Cognitive Problems in Perimenopause: A Review of Recent Evidence

Metcalf, Christina A.; Duffy, Korrina A.; Page, Chloe E.; Novick, Andrew M.

doi:10.1007/s11920-023-01447-3

Cited by 11 publications

(3 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of dementia due to modifiable risk factors (hearing loss, traumatic brain injury, hypertension, alcohol use and obesity) cumulatively come up to 15% in midlife as reported by the Lancet Commission 21 . Also, there are associated cognitive performance measures getting affected with perimenopausal age and less studied in our population 22,23 . Due to these factors, it is beneficial to look at cognitive trajectories in adults (middle-aged and above) without dementia (Clinical Dementia Rating Score < 1) and follow them up regularly to identify pre-dementia syndromes (Subjective Cognitive Decline, Motoric Cognitive Risk Syndrome, Mild Cognitive Impairment) while comprehensively evaluating for risk factors and comorbidities (diabetes, features of metabolic syndrome like hypertension, dyslipidemia etc.)…”

Section: Study Populationmentioning

confidence: 84%

Prevalence and patterns of vitamin D deficiency and its role in cognitive functioning in a cohort from South India

Ghosh,

Sunny

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Vitamin D (VitD) is a naturally occurring, fat-soluble vitamin which regulates calcium and phosphate homeostasis in the human body and is also known to have a neuroprotective role. VitD deficiency has often been associated with impaired cognition and a higher risk of dementia. In this study, we aimed to explore the relationship between levels of VitD and cognitive functioning in adult individuals. 982 cognitively healthy adults (≥ 45 years) were recruited as part of the CBR-Tata Longitudinal Study for Aging (TLSA). Addenbrooke’s cognitive examination-III (ACE-III) and Hindi mental status examination (HMSE) were used to measure cognitive functioning. 25-hydroxyvitamin D [25(OH)D] levels were measured from the collected serum sample and classified into three groups— deficient (< 20 ng/ml), insufficient (20–29 ng/ml) and normal (≥ 30 ng/ml). Statistical analysis was done using IBM SPSS software, version 28.0.1.1(15). The mean age of the participants was 61.24 ± 9 years. Among 982 participants, 572 (58%) were deficient, 224 (23%) insufficient and only 186 (19%) had normal levels of VitD. Kruskal–Wallis H test revealed a significant difference in age (p = 0.015) and education (p = 0.021) across VitD levels and the Chi-square test revealed a significant association between gender (p = 0.001) and dyslipidemia status (p = 0.045) with VitD levels. After adjusting for age, education, gender and dyslipidemia status, GLM revealed that individuals with deficient (p = 0.038) levels of VitD had lower scores in ACE-III verbal fluency as compared to normal. Additionally, we also found that 91.2% individuals who had VitD deficiency were also having dyslipidemia. It is concerning that VitD deficiency impacts lipid metabolism. Lower levels of VitD also negatively impacts verbal fluency in adult individuals. Verbal fluency involves higher order cognitive functions and this result provides us with a scope to further investigate the different domains of cognition in relation to VitD deficiency and other associated disorders.

show abstract

Section: Study Populationmentioning

confidence: 84%

Prevalence and patterns of vitamin D deficiency and its role in cognitive functioning in a cohort from South India

Ghosh,

Sunny

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The decline in ovarian function and prolonged estrogen deprivation during the menopausal transition are known to affect psychological and cognitive wellbeing [7]. Research has shown that female patients in the menopausal transition and early postmenopausal years are more likely to experience depressive moods than premenopausal female patients [8,44].…”

Section: Hormonal Changes During Perimenopausementioning

confidence: 99%

“…Epidemiological studies have shown that approximately 20% of women may experience an episode of MDD at some point in their lives [6]. Furthermore, the risk of depression appears to increase during dynamic hormonal flux periods such as the perimenopause stage [7], with rates of MDD and clinical elevations in depressive symptoms doubling to tripling when compared to premenopausal and late postmenopausal rates [8]. Perimenopausal depression is a type of depression that occurs during the perimenopausal period, which is characterized by the simultaneous occurrence of multiple menopausal symptoms that overlap with emotional disorders, like depression and no interest, sleep disorders, tiredness, low energy, no selfconfidence, and thoughts of death [9].…”

Section: Introductionmentioning

confidence: 99%

Menopause-Associated Depression: Impact of Oxidative Stress and Neuroinflammation on the Central Nervous System—A Review

Liang,

Kow,

Yusof

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Perimenopausal depression, occurring shortly before or after menopause, is characterized by symptoms such as emotional depression, anxiety, and stress, often accompanied by endocrine dysfunction, particularly hypogonadism and senescence. Current treatments for perimenopausal depression primarily provide symptomatic relief but often come with undesirable side effects. The development of agents targeting the specific pathologies of perimenopausal depression has been relatively slow. The erratic fluctuations in estrogen and progesterone levels during the perimenopausal stage expose women to the risk of developing perimenopausal-associated depression. These hormonal changes trigger the production of proinflammatory mediators and induce oxidative stress, leading to progressive neuronal damage. This review serves as a comprehensive overview of the underlying mechanisms contributing to perimenopausal depression. It aims to shed light on the complex relationship between perimenopausal hormones, neurotransmitters, brain-derived neurotrophic factors, chronic inflammation, oxidative stress, and perimenopausal depression. By summarizing the intricate interplay between hormonal fluctuations, neurotransmitter activity, brain-derived neurotrophic factors, chronic inflammation, oxidative stress, and perimenopausal depression, this review aims to stimulate further research in this field. The hope is that an increased understanding of these mechanisms will pave the way for the development of more effective therapeutic targets, ultimately reducing the risk of depression during the menopausal stage for the betterment of psychological wellbeing.

show abstract

Menopause and Traumatic Brain Injury: A NIDILRR Collaborative Traumatic Brain Injury Model Systems Study

Rapport,

Kalpakjian,

Sander

et al. 2024

Archives of Physical Medicine and Rehabilitation

View full text Add to dashboard Cite

Cognitive Problems in Perimenopause: A Review of Recent Evidence

Cited by 11 publications

References 68 publications

Prevalence and patterns of vitamin D deficiency and its role in cognitive functioning in a cohort from South India

Prevalence and patterns of vitamin D deficiency and its role in cognitive functioning in a cohort from South India

Menopause-Associated Depression: Impact of Oxidative Stress and Neuroinflammation on the Central Nervous System—A Review

Menopause and Traumatic Brain Injury: A NIDILRR Collaborative Traumatic Brain Injury Model Systems Study

Contact Info

Product

Resources

About